CVS Caremark Updates Formularies to Prioritize Biosimilars, Targeting $0 Out‑of‑Pocket for Members
CVS Caremark announced July 1, 2026 updates to its most common commercial template formularies that will prefer FDA‑approved interchangeable biosimilars over select brand drugs, including Stelara. The changes are designed to deliver $0 out‑of‑pocket costs for many members while preserving clinical quality. The move signals a broader push by the pharmacy‑benefit manager to curb rising drug prices.
The BioPharm Brief: Precision, Immunotherapy, Expansion
Madrigal Pharmaceuticals is licensing Arrowhead’s RNA‑interference candidate ARO‑PNPLA3 to broaden its precision‑medicine pipeline for metabolic dysfunction‑associated steatohepatitis (MASH). LTZ Therapeutics secured $38 million to push forward myeloid‑engager immunotherapies that activate innate immune cells against cancer. Amgen and Eli Lilly announced major U.S....
IBM, Cleveland Clinic, RIKEN Simulate Record 12,635‑Atom Protein on Quantum Computers
IBM, Cleveland Clinic and Japan’s RIKEN have jointly simulated a 12,635‑atom protein using quantum‑centric supercomputing, a 40‑fold increase over their previous benchmark and a 210‑times accuracy improvement. The work demonstrates that quantum processors can now tackle biologically relevant molecular systems...
FDA Clears Regeneron's Otarmeni, First Gene Therapy for Hearing Loss
The U.S. Food and Drug Administration has approved Otarmeni, Regeneron's gene‑therapy drug for OTOF‑related hearing loss, marking the first FDA‑cleared treatment that restores auditory function. The therapy, free for U.S. patients, could affect up to 200,000 people worldwide with this...
Staying the Course: TMDX’s Long‑Term Thesis Remains Intact
Excellent post (below) on $TMDX, I'll do another detailed post in the next few days however in the meantime I'm doing calls with sell-side analysts and management. Here's what I'll say for now... Today is obviously frustrating for long-term shareholders but I...
Death-Defying Protein Found in Tardigrades Preserves Synthetic Cells
Researchers at the University of Michigan and the University of Chicago have shown that the tardigrade‑derived protein CAHS12 can protect synthetic cells from dehydration. By embedding CAHS12 into lipid‑bound vesicles, the engineered cells survived drying and regained protein‑making activity after...
DNA-Guided CRISPR Flips Gene Editing Script, Opening a New Path for Precise Diagnosis and Antivirals
Researchers at Hong Kong University of Science and Technology have created the first DNA‑guided CRISPR‑Cas12a system that can programmatically target and cleave RNA. The new platform, called SLEUTH, combines the DNA‑guided enzyme with isothermal amplification to achieve attomolar‑level detection of...
Peptides Boost Hormones, Yet Trigger Serious Metabolic Side Effects
People mistakenly believe peptides are only good. Peptides can be bad, too. They can cause adverse effects. Some dangerous. I did a peptide experiment and measured its effects in my body. The results are complicated. I tried a peptide called CJC-1295....
What’s New in Clinical Trial Innovation
The FDA’s Center for Clinical Trial Innovation (C3TI) publishes a newsletter that highlights new developments, opportunities, and initiatives in clinical‑trial innovation. Readers can subscribe via a public.govdelivery.com form to receive updates directly in their inbox. The site also provides free...
Hamilton Unveils Integrated Glucose Sensor, Marks Decade Milestone
Hamilton Company has been coming to @SynBioBeta for years. This year, they showed up with something new. Tyler Schweder from Hamilton's process analytics team walked Gary George through their full upstream workflow: pH, dissolved oxygen, viable cell density, total cell...
The Human Genome Encodes for a New Category of Molecule
Scientists have identified a previously unrecognized class of molecules encoded within the human genome, arising from short open reading frames once deemed non‑coding. These micro‑proteins, often called micropeptides, exhibit distinct biochemical activity and appear to regulate cellular pathways. Early experimental...
These Companies Help Parents Try to Pick Their Babies' Traits. Experts Are Wary
Companies such as Herasight, Orchid Health and Nucleus Genomics now offer polygenic embryo screening that estimates disease risk and predicts traits like height, BMI, longevity and IQ. The service relies on polygenic risk scores derived from DNA samples of parents...
Treating Cancer Based on Mutation Alone Does Not Improve Survival
A large Australian study of 3,383 advanced‑cancer patients found that targeted therapies approved for a specific mutation within the same tumor type improved overall survival by roughly 40%, while using a drug solely because of a shared mutation across different...
Metabolic Stability in Peptide Therapeutics
Peptide therapeutics are gaining traction but remain hampered by poor metabolic stability, limited permeability, and rapid clearance. The article outlines four primary metabolic pathways—hydrolysis, oxidation, reduction, and conjugation—and examines the hurdles of oral delivery, in‑vitro tools, and experimental workflows used...
AstraZeneca’s Camizestrant Hit by FDA Advisory Committee Vote While Truqap Moves Ahead
FDA’s Oncologic Drugs Advisory Committee issued a split verdict on AstraZeneca’s oncology pipeline this week. The committee voted 3‑to‑6 against the benefit‑risk profile of camizestrant combined with a CDK4/6 inhibitor for ESR1‑mutated advanced breast cancer, despite a 56% progression‑free survival...
OECD Blog Item Explores Why Biotech Start-Ups Lag in Europe
The OECD’s May 6 blog highlights that Europe continues to fall behind the United States and Asia in biotech start‑up formation, patenting, and venture‑capital funding. It points to the European Commission’s December 2025 Biotech Act, which introduces regulatory sandboxes, pre‑submission consultations, a...
Bayer Sees Opportunity With $300M Acquisition of Eye Drug Biotech
Bayer announced a $300 million upfront acquisition of Perfuse Therapeutics, a clinical‑stage biotech developing PER‑001, an endothelin‑receptor blocker delivered via a six‑month intravitreal implant. Phase 2 trials showed significant vision improvement in glaucoma and diabetic retinopathy, positioning the drug as a potential...
Pharmaceutical Executive Daily: Zentalis Doses First Patient with Azenosertib in Phase III Trial
Zentalis Pharmaceuticals announced the first patient dosing in the Phase III Aspenova trial of Azenosertib, an oral WEE1 inhibitor for Cyclin E1‑positive, platinum‑resistant ovarian cancer. The study is run with the GOG Foundation, the European Network of Gynecological Oncology Trials (EN‑GOT), and...
HOPE Supports Tailored Approach to BP After Stroke Thrombectomy
The HOPE trial, presented at the European Stroke Organisation Conference 2026, tested a reperfusion‑guided blood‑pressure strategy after endovascular thrombectomy for acute ischemic stroke. Patients whose post‑procedure mTICI score was 2b were targeted to a systolic BP of 140‑160 mm Hg, while those...
Brolucizumab Superior in Preserving Visual Acuity in Proliferative Diabetic Retinopathy
A phase‑3 CONDOR trial of 689 adults with proliferative diabetic retinopathy (PDR) showed that intravitreal brolucizumab outperformed panretinal laser photocoagulation (PRP) in preserving visual acuity over 54 weeks. The brolucizumab arm gained a mean BCVA change of +0.2 letters versus...
Assessing Candidate IGF-1 Receptor Inhibitors for the Ability to Modestly Slow Aging in Mice
The study tested two small‑molecule IGF‑1 receptor inhibitors, picropodophyllin (PPP) and NVP‑ADW742, in 13‑month‑old C57BL/6 mice to assess healthspan and survival. Both drugs improved memory, blood pressure, glucose tolerance and frailty metrics, with NVP‑ADW742 extending healthspan by about 93 days....
Light without Electricity? Glowing Algae Could Make It Possible
University of Colorado Boulder researchers discovered that acidic (pH 4) or basic (pH 10) solutions can sustain the bioluminescence of Pyrocystis lunula algae for up to 25 minutes. By embedding the algae in a water‑based hydrogel and 3D‑printing it into shapes, they...
Clinical Trials Day
Clinical Trials Day on May 20 commemorates James Lind’s 1747 scurvy experiment, widely regarded as the first randomized clinical trial. The observance highlights the enduring role of trials in generating the safety and efficacy data that underpin FDA drug approvals. FDA’s...
BsUFA IV: Fiscal Years 2028-2032
The FDA announced the kickoff of the fourth Biosimilar User Fee Act (BsUFA IV) reauthorization, covering fiscal years 2028‑2032. A public meeting was held on December 3, 2025 to launch the process, following the 2022 law that reauthorized BsUFA II. BsUFA III expires in September 2027,...
In a First, Scientists Are Rewinding Human Cells Back to a ‘Youthful’ State. Is This the Dawn of Immortality?
Scientists are advancing partial cellular reprogramming to reverse age‑related decline while preserving cell identity. YouthBio Therapeutics is preparing a first‑in‑human trial of its brain‑targeted YB002 program for Alzheimer’s after receiving FDA feedback. Parallel efforts such as Life Biosciences’ ER‑100 aim...
PRP Therapy Protocols Lack Expert Consensus
Platelet‑rich plasma (PRP) therapy lacks a unified peri‑procedural protocol, with leading experts disagreeing on NSAID washout periods, supplement restrictions, cryotherapy, and rehabilitation timing. The article highlights that ten top clinicians offered divergent recommendations on pre‑procedure NSAID use, corticosteroid washout, and...
Thailand Leads Longevity Tourism with 90‑Day Visas and Low‑Cost Regeneration
Thailand’s Tourism Authority has positioned the kingdom as the world’s premier longevity‑tourism destination, rolling out 90‑day multi‑entry medical visas and marketing the slogan “Healing is the New Luxury.” The move couples high‑tech clinics with cultural practices, delivering regenerative programs that...
Celcuity’s Gedatolisib Beats Novartis’ Piqray in Phase III Advanced Breast Cancer Trial
Celcuity announced that its PI3K‑mTOR inhibitor gedatolisib achieved a progression‑free survival benefit versus Novartis' alpelisib (Piqray) in a Phase III study of advanced breast cancer patients with PIK3CA mutations. The data could reshape treatment options for a disease that affects millions...
FDA Vaccine Studies Censored by Trump Admin After Finding Benefits of Shots
The Food and Drug Administration, under the Department of Health and Human Services, blocked the publication of two internal studies that demonstrated the safety and efficacy of COVID‑19 vaccines, and prevented two Shingrix (shingles vaccine) abstracts from being presented at...
Pfizer Posts $14.5 B Q1 Revenue, Reaffirms 2026 Guidance
Pfizer announced first‑quarter 2026 revenue of $14.5 billion, a 5% year‑over‑year increase, and a 22% rise in operational revenue from launched and acquired products. The company reaffirmed its full‑year 2026 financial guidance while highlighting progress in oncology and obesity pipelines.
S-Mitochonic Acid 5. Increases ATP, NAD+ and SIRTUINS
Researchers have synthesized the S‑enantiomer of Mitochonic Acid‑5 (MA‑5) with 99 % enantiomeric purity. The compound strengthens the mitochondrial protein Mitofilin, preserving crista junction geometry and boosting ATP synthase efficiency. It also acts as a direct NAMPT agonist, raising intracellular NAD⁺,...
Tofersen, a New Treatment for A.L.S., Reverses Symptoms for Some
Tofersen, the first FDA‑approved therapy targeting the SOD1 genetic form of ALS, is showing functional gains in a subset of patients. In a case highlighted by the New York Times, 58‑year‑old Amanda Sifford’s lung capacity rebounded from 48% to 86%...
LTZ Therapeutics Secures $38M to Advance Myeloid Engager Immunotherapy Pipeline
LTZ Therapeutics announced an oversubscribed $38 million financing round led by GL Ventures, bringing its total capital to roughly $130 million since 2022. The funds will propel the Universal Myeloid Cell Engager (U‑MCE) platform, supporting the Phase 1 trial of lead bispecific antibody...
COVID-19 Prevention Gaps in Immunocompromised Patients: Muhammed Bilal Abid, MD
Dr. Muhammed Bilal Abid highlighted persistent COVID‑19 prevention gaps for immunocompromised patients, especially those with chronic lymphocytic leukemia (CLL). He cited the CANOPY trial, which reported zero symptomatic COVID‑19 cases over six months in a small CLL cohort receiving the monoclonal antibody...
Latus Bio Secures $97 Million Series A to Scale Gene‑Therapy Access
Latus Bio closed a $97 million Series A financing, with a $43 million extension led by 8VC, to accelerate its AAV‑based gene‑therapy pipeline. The capital will fund IND filing for Huntington’s disease candidate LTS‑201 and a CLN2 trial, underscoring investor confidence in...
Heavy-Chain BsAbs More Manufacturable than Light-Chains
Bispecific antibodies (BsAbs) have grown to 19 FDA approvals and roughly 250 candidates in development, but scaling their production remains a bottleneck. A recent study by Universidad Nacional Autónoma de México researchers compared six BsAb architectures and linked design to...
Researchers’ Spinout Focuses on Simplifying Viral Vector Purification
Researchers at North Carolina State University have spun out ChromaGenix to commercialize synthetic peptide ligands for affinity purification of viral vectors used in gene therapies. The peptide ligands are cheaper, more stable and less immunogenic than traditional protein ligands, cutting...
Moss Powering the Next Drug Frontier
Eleva is commercializing a moss‑based biomanufacturing platform that can produce complex glycoproteins difficult to express in traditional CHO or yeast systems. The German firm has advanced its first candidate, a recombinant alpha‑galactosidase for Fabry disease, into clinical trials and is...
Regulators Should Rely on Peers’ GMP Audits to Cut Inspection Burden
Biopharma manufacturing sites face an average of 2.68 GMP inspections per year, each lasting up to nine days, and preparation can take six months to a year. The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) argues that regulators should...
First U.S. Patients Treated With Microrobotic Surgery For Alzheimer’s
A microrobotic surgery trial for Alzheimer’s disease began at Baptist Health in Jacksonville, treating the first patient with moderate disease. Medical Microinstruments Inc. (MMI) plans to enroll 15 participants and monitor them for a year, aiming to clear cervical lymph‑node...
Financings for May 6, 2026
UK‑based Cytospire Therapeutics announced a £61 million (≈$82.7 million) Series A round to accelerate its EGFR‑targeted T‑cell engager pipeline for solid tumours. The capital backs multiple pre‑clinical programs and reflects strong investor confidence in next‑generation immunotherapies. Bio Korea 2026 highlighted a shift in...
Snowflake and Veeva Unlock Agentic AI in Life Sciences
Snowflake and Veeva announced a joint solution that links Veeva Vault’s read‑only data to Snowflake’s AI Data Cloud via the Openflow Connector. The integration lets life‑science firms run end‑to‑end analytics and agentic AI across clinical, safety, regulatory, quality and commercial...
Other News to Note for May 6, 2026
Cytospire Therapeutics announced a £61 million (≈$82.7 million) Series A round to advance its next‑generation T‑cell engager platform targeting the epidermal growth factor receptor (EGFR) in solid tumours. The funding will accelerate pre‑clinical and early‑clinical programs aimed at delivering more selective immunotherapies. Meanwhile,...
Eli Lilly Opens First Dedicated Genetic Medicine Facility
Eli Lilly inaugurated Lilly Lebanon Advanced Therapies, its first dedicated genetic‑medicine manufacturing site in Lebanon, Indiana, alongside a $4.5 billion capital infusion. The investment lifts Lilly’s Indiana spending to over $21 billion since 2020 and its U.S. commitments to more than $50 billion. The...
Briumvi’s Optional Subq Gives It Market‑share Edge
On the $TGTX call the following was casually mentioned in response to a question about subq: "We feel actually very confident in our ability to deliver a quarterly product." It's important to understand that Briumvi will be the only product that...
CoCoGraph AI Model Generates Molecules that Comply with Rules of Chemistry
Researchers at Universitat Rovira i Virgili have unveiled CoCoGraph, an AI diffusion model that generates synthetic molecules while strictly adhering to fundamental chemical rules. By progressively disordering and reconstructing real molecules, the system ensures valid bond counts and produces chemically...
Dark Proteome Research Redefines Human Disease Understanding
This, from @MeganMolteni, is frickin' cool. "How a global effort to explore the ‘dark proteome’ is upending our understanding of human disease." I remember when everyone was shocked that there were only 30,000 protein-coding genes found by the Human Genome Project. This...
80+ Therapeutic Peptides Approved Across Major Disease Areas
Did you know... over 80 therapeutic peptides have been approved to treat a wide array of diseases, ranging from infectious diseases, cardiovascular, dysmetabolic diseases, and cancer: https://t.co/kW4zgAcmE3
Scientists Remove Essential Amino Acid, Redefining Life's Code
All Life Uses 20 Amino Acids. Scientists Just Deleted One in Bacteria The synthetic bacteria push the limits of life and could open the door to designer proteins and new medicines https://t.co/mVZrQ0z7vz https://t.co/zFzSpnrk6h
Pill GLP‑1 Drugs Activate Amygdala Reward Circuit, Not Hypothalamus
Discovery of a new brain reward circuit in the amygdala for small molecule (pill) GLP-1 drug effect, unlike the injectables (hypothalamus), as shown in mice https://t.co/3lkfxROh5Z